Developments Jazz, Zymeworks post positive Phase 2 survival in metastatic gastroesophageal adenocarcinoma Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) reported the first overall survival (OS) data from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in... January 19, 2023